The Taiwan-listed company said its allogeneic off-the-shelf CAR-T therapy showed a favorable Phase I safety profile and early efficacy signals in treatment-resistant solid tumors including GBM and MSS CRC.
verifying reliability
No specialized terms available for this topic.